Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw an uptick in trading volume on Friday . 54,091 shares were traded during mid-day trading, an increase of 52% from the previous session's volume of 35,631 shares.The stock last traded at $17.83 and had previously closed at $17.18.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Oculis in a research note on Wednesday, October 23rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Oculis presently has a consensus rating of "Buy" and an average target price of $29.20.
View Our Latest Report on Oculis
Oculis Trading Up 4.1 %
The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. The firm has a market cap of $724.14 million, a PE ratio of -9.31 and a beta of 0.30. The firm has a fifty day simple moving average of $13.38 and a two-hundred day simple moving average of $12.39.
Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. The company had revenue of $0.27 million during the quarter, compared to analysts' expectations of $0.28 million. Equities analysts forecast that Oculis Holding AG will post -2.19 EPS for the current year.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
